Risk Factors for Contralateral Occult Papillary Thyroid Carcinoma in Patients with Clinical Unilateral Papillary Thyroid Carcinoma: A Case-Control Study
Table 1
Distribution of clinical and pathological characteristics in 229 patients.
Variables
Group
Statistical values
Case (N = 46)
Control (N = 183)
F
Chi-square
P
Age, years, mean ± SD
39.20 ± 11.65
39.06 ± 11.80
0.67
0.944
Gender, %
0.00
0.983
Female
32 (69.6)
127 (69.4)
Male
14 (30.4)
56 (30.6)
BMI, mean ± SD
24.00 ± 3.34
24.34 ± 3.94
1.47
0.592
Multifocality, %
5.59
<0.05
Presence
24 (52.2)
61 (33.3)
Absence
22 (47.8)
122 (66.7)
Location, %
0.28
0.597
Upper
12 (26.1)
55 (30.1)
Otherwise
34 (73.9)
128 (69.9)
Diameter, %
0.32
0.574
<1 cm
18 (39.1)
80 (43.7)
≥1 cm
28 (60.9)
103 (56.3)
Diameter of COPTC %
<3 mm
36 (78.3)
—
≥3 mm
10 (32.7)
—
Capsule, %
5.64
<0.05
Intact
20 (43.5)
47 (25.7)
Invasion
26 (56.5)
136 (74.3)
Trachea invasion, %
0.14
0.706
Presence
3 (6.5)
15 (8.2)
Absence
43 (93.5)
168 (91.8)
Strap muscle invasion, %
0.10
0.753
Presence
5 (10.9)
23 (12.6)
Absence
41 (89.1)
163 (87.4)
CNM, %
4.63
<0.05
Presence
39 (84.8)
126 (68.9)
Absence
7 (15.2)
57 (31.1)
LNM, %
1.24
0.265
Presence
32 (69.6)
111 (60.7)
Absence
14 (30.4)
72 (39.3)
B-RAF mutation, %
0.13
0.716
Presence
35 (76.1)
143 (78.6)
Absence
11 (23.9)
39 (21.4)
Serum Tg, %
2.38
0.304
≤5 μg/L
4 (10.3)
32 (20.4)
5∼40 μg/L
20 (51.2)
77 (49.0)
>40 μg/L
15 (38.4)
48 (30.6)
HT, %
4.52
<0.05
Presence
20 (43.5)
50 (27.3)
Absence
26 (56.5)
133 (72.7)
Thirty-three patients did not have a preoperative serum thyroglobulin test.
